DE69027187T2 - Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen - Google Patents
Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungenInfo
- Publication number
- DE69027187T2 DE69027187T2 DE69027187T DE69027187T DE69027187T2 DE 69027187 T2 DE69027187 T2 DE 69027187T2 DE 69027187 T DE69027187 T DE 69027187T DE 69027187 T DE69027187 T DE 69027187T DE 69027187 T2 DE69027187 T2 DE 69027187T2
- Authority
- DE
- Germany
- Prior art keywords
- viruses
- blood
- virus
- blood product
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000000415 inactivating effect Effects 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 8
- 239000010836 blood and blood product Substances 0.000 claims abstract description 47
- 229940125691 blood product Drugs 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 44
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims abstract description 39
- 102000004506 Blood Proteins Human genes 0.000 claims abstract description 32
- 108010017384 Blood Proteins Proteins 0.000 claims abstract description 32
- 230000008569 process Effects 0.000 claims abstract description 18
- 239000000645 desinfectant Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 21
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 20
- 239000012141 concentrate Substances 0.000 abstract description 13
- 238000005194 fractionation Methods 0.000 abstract description 11
- 208000006454 hepatitis Diseases 0.000 abstract description 10
- 231100000283 hepatitis Toxicity 0.000 abstract description 10
- 239000006228 supernatant Substances 0.000 abstract description 8
- 238000000108 ultra-filtration Methods 0.000 abstract description 8
- 238000004925 denaturation Methods 0.000 abstract description 5
- 230000036425 denaturation Effects 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 5
- 238000009877 rendering Methods 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 description 53
- 102100022641 Coagulation factor IX Human genes 0.000 description 45
- 108010076282 Factor IX Proteins 0.000 description 45
- 229960004222 factor ix Drugs 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 39
- 239000000306 component Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000003114 blood coagulation factor Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 241000700721 Hepatitis B virus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 9
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229960000380 propiolactone Drugs 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108010094028 Prothrombin Proteins 0.000 description 7
- -1 etc.) Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100026735 Coagulation factor VIII Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010054218 Factor VIII Proteins 0.000 description 5
- 102000001690 Factor VIII Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960000301 factor viii Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000004252 protein component Nutrition 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 208000009429 hemophilia B Diseases 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010023321 Factor VII Proteins 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 208000037319 Hepatitis infectious Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 102000005686 Serum Globulins Human genes 0.000 description 3
- 108010045362 Serum Globulins Proteins 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 229940012426 factor x Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229960000027 human factor ix Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 230000031915 positive regulation of coagulation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 2
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010005642 Properdin Proteins 0.000 description 1
- 102100038567 Properdin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003686 blood clotting factor concentrate Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 238000010261 blood fractionation Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000535 fibrinogen concentrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36685589A | 1989-06-15 | 1989-06-15 | |
| PCT/US1990/003355 WO1990015613A1 (en) | 1989-06-15 | 1990-06-13 | Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69027187D1 DE69027187D1 (de) | 1996-07-04 |
| DE69027187T2 true DE69027187T2 (de) | 1996-10-31 |
Family
ID=23444851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69027187T Expired - Lifetime DE69027187T2 (de) | 1989-06-15 | 1990-06-13 | Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5300433A (es) |
| EP (1) | EP0431129B1 (es) |
| JP (1) | JP3297433B2 (es) |
| AT (1) | ATE138575T1 (es) |
| CA (1) | CA2034489C (es) |
| DE (1) | DE69027187T2 (es) |
| DK (1) | DK0431129T3 (es) |
| ES (1) | ES2087156T3 (es) |
| WO (1) | WO1990015613A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402891B (de) * | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| AT408191B (de) * | 1991-08-19 | 2001-09-25 | Haemosan Erzeugung Pharmazeuti | Verfahren zur inaktivierung von prionen |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| AT399818B (de) * | 1992-04-24 | 1995-07-25 | Immuno Ag | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation |
| EP0674531A1 (de) * | 1992-12-16 | 1995-10-04 | IMMUNO Aktiengesellschaft | Verfahren zur herstellung eines virussicheren biologischen präparates |
| DE4320294A1 (de) * | 1993-06-18 | 1994-12-22 | Immuno Ag | Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen |
| DE4434538C2 (de) * | 1993-10-06 | 2000-08-10 | Immuno Ag | Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens |
| HRP940645A2 (en) * | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| WO1996032130A1 (en) * | 1995-04-10 | 1996-10-17 | Baxter International Inc. | The use of cross-linked hemoglobin in treating subarachnoid hemorrhage |
| US5741894A (en) * | 1995-09-22 | 1998-04-21 | Baxter International, Inc. | Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form |
| US6005077A (en) * | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| US7026468B2 (en) * | 1996-07-19 | 2006-04-11 | Valentis, Inc. | Process and equipment for plasmid purification |
| US7807822B2 (en) * | 1996-08-01 | 2010-10-05 | Robert Bridenbaugh | Methods for purifying nucleic acids |
| UA64742C2 (uk) * | 1997-12-24 | 2004-03-15 | Альфа Терапевтик Корпорейшн | СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ) |
| US6270723B1 (en) * | 1998-06-15 | 2001-08-07 | Bbi Bioseq, Inc. | Rapid cryobaric sterilization and vaccine preparation |
| US6441144B1 (en) | 1999-05-20 | 2002-08-27 | Alpha Therapeutic Corporation | Method for repairing dual virally inactivated immune globulin for intravenous administration |
| US6747132B2 (en) * | 2000-11-29 | 2004-06-08 | Apex Biosciences, Inc. | Methods for the synthesis of a modified hemoglobin solution |
| US7038016B2 (en) | 2001-08-21 | 2006-05-02 | Apex Bioscience, Inc. | Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution |
| DE60326001D1 (de) * | 2002-02-22 | 2009-03-12 | Intracel Recources Llc | Sterile immunogene nicht-tumorigene tumorzell-zusammensetzungen und verfahren |
| CA2498518A1 (en) * | 2002-09-13 | 2004-03-25 | Valentis, Inc. | Apparatus and method for preparative scale purification of nucleic acids |
| AU2005227090B2 (en) * | 2004-03-22 | 2010-12-09 | Abbott Laboratories Gmbh | Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
| US20060110405A1 (en) * | 2004-08-20 | 2006-05-25 | Buckheit Robert W Jr | Plasma or serum fraction for treatment and prevention of viral infections and related conditions |
| UA93384C2 (ru) * | 2005-07-29 | 2011-02-10 | Солвей Фармасьютикалс Гмбх | Способ получения стерилизированного порошкообразного панкреатина |
| US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| WO2012069474A2 (en) * | 2010-11-24 | 2012-05-31 | H. Lundbeck A/S | A method for reducing potential virus burden in a sample by cyanate treatment |
| WO2012082933A1 (en) | 2010-12-15 | 2012-06-21 | Baxter International, Inc. | Eluate collection using conductivity gradient |
| LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| JPS61500226A (ja) * | 1983-10-28 | 1986-02-06 | ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド | コンホメ−ション特異性抗体を用いる血液凝固タンパク質の精製および単離法 |
| US4673733A (en) * | 1985-04-11 | 1987-06-16 | Sudhish Chandra | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents |
| AT385203B (de) * | 1985-04-26 | 1988-03-10 | Immuno Ag | Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| DD264137A1 (de) * | 1987-09-22 | 1989-01-25 | Univ Leipzig | Mittel zur bekaempfung von viren in kulturpflanzen |
-
1990
- 1990-06-13 DE DE69027187T patent/DE69027187T2/de not_active Expired - Lifetime
- 1990-06-13 AT AT90909877T patent/ATE138575T1/de not_active IP Right Cessation
- 1990-06-13 ES ES90909877T patent/ES2087156T3/es not_active Expired - Lifetime
- 1990-06-13 EP EP90909877A patent/EP0431129B1/en not_active Expired - Lifetime
- 1990-06-13 CA CA002034489A patent/CA2034489C/en not_active Expired - Lifetime
- 1990-06-13 DK DK90909877.4T patent/DK0431129T3/da active
- 1990-06-13 JP JP50988190A patent/JP3297433B2/ja not_active Expired - Lifetime
- 1990-06-13 WO PCT/US1990/003355 patent/WO1990015613A1/en active IP Right Grant
-
1991
- 1991-09-25 US US07/765,479 patent/US5300433A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990015613A1 (en) | 1990-12-27 |
| EP0431129A1 (en) | 1991-06-12 |
| ES2087156T3 (es) | 1996-07-16 |
| JP3297433B2 (ja) | 2002-07-02 |
| EP0431129B1 (en) | 1996-05-29 |
| EP0431129A4 (en) | 1992-03-11 |
| CA2034489A1 (en) | 1990-12-16 |
| JPH04501429A (ja) | 1992-03-12 |
| US5300433A (en) | 1994-04-05 |
| CA2034489C (en) | 1996-07-16 |
| ATE138575T1 (de) | 1996-06-15 |
| DE69027187D1 (de) | 1996-07-04 |
| DK0431129T3 (da) | 1996-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69027187T2 (de) | Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen | |
| DE68913422T2 (de) | Entfernen von Verfahrenschemikalien aus labilen biologischen Gemischen durch hydrophobe Austauschchromatographie. | |
| AT402607B (de) | Verfahren zur gewinnung einer ein labiles verfahren zur gewinnung einer ein labiles protein enthaltenden zusammensetzung protein enthaltenden zusammensetzung | |
| DE3033932C2 (de) | Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten | |
| DE69831684T2 (de) | Verfahren zur Herstellung von hochvirusfreiem Thrombin zur Bereitung von Fibrinkleber aus menschlichem Plasma-Pool | |
| DE3734923C1 (de) | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt | |
| EP0330047B1 (de) | Verfahren zur Sterilisation von Blut, Plasma, Blut- und Plasmaderivaten, Zellsuspensionen oder dgl. | |
| JP4211894B2 (ja) | 血漿から得られるフィブリノーゲン濃縮物及びその製法 | |
| DE69434445T2 (de) | Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt | |
| EP0268973A2 (de) | Verfahren zur Herstellung eines virussicheren, lagerstabilen und intravenös verträglichen Immunglobulin-G-Präparates | |
| WO1990005520A2 (en) | Tissue culture antiviral processes and compositions | |
| EP0352500A2 (de) | Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen immunoglobulin-Präparates mit hohemIgM-Gehalt. | |
| DE29624488U1 (de) | Anlage zur Inaktivierung von in Blutprodukten enthaltenen Kontaminierungen | |
| EP0973544B1 (de) | Immuntolerante prothrombinkomplex-präparation | |
| DE3733181C1 (de) | Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates | |
| AT390560B (de) | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern | |
| EP0692491B1 (de) | Virussicheres stabiles pharmazeutisches Präparat bestehend aus wenigstens 70%, bevorzugt 90% humanem monomerem Immunglobulin A und Verfahren zu seiner Herstellung | |
| DE69627319T2 (de) | Herstellung von immunglobulin | |
| EP0679405A1 (de) | Verfahren zur Abtrennung von Viren aus Proteinlösungen | |
| EP0234405B1 (de) | Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen | |
| JPH06511013A (ja) | 血液、組織および生物流体のアルブミンーヨウ素保存 | |
| EP1053754B1 (de) | Verfahren zur Inaktivierung von Viren | |
| EP0873362B1 (de) | VERFAHREN ZUR TRENNUNG VON IgG und IgA | |
| EP0988063B1 (de) | Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material | |
| US20160289300A1 (en) | Method of manufacturing intravenous immunoglobulin from fraction iii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC |